19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.
CARDIOVASCULAR EFFECTS OF ANTHRACYCLINE-LIKE CHEMOTHERAPY AGENTS JOHN N. HAMATY FACC, FACOI.
Causes Myocardial dysfunction eg IHD, CM Volume overload eg AR, MR Obstruction eg AS, HCM Diastolic dysfunction eg Constriction Mechanical problems eg.
ACLS Drugs
Transplantation For Scleroderma: Data from the Phase I/II Pilot Multicenter Study (FHCRC protocol 1019)
HEART FAILURE Jamil Mayet Consultant Cardiologist.
The SIGNIFY study
VIRAL MYOCARDITIS AN UPDATE
